p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition.

Overview of attention for article published in Molecular Cancer Therapeutics, September 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (51st percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Readers on

mendeley: 7 Mendeley

Summary X

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 1,834 followers.

p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition. https://t.co/ajBtZjnAPH https://t.co/IZqolFhcmU

22 Nov 2022

Reply Repost Favourite

p53 pathway inactivation drives SMARCB1-deficient p53-wildtype epithelioid sarcoma onset indicating therapeutic vulnerability through MDM2 inhibition https://t.co/zlXz6t3DOw https://t.co/GPd4UAGDuk

14 Sep 2022

Reply Repost Favourite

p53 pathway inactivation drives SMARCB1-deficient p53-wildtype epithelioid sarcoma onset indicating therapeutic vulnerability through MDM2 inhibition https://t.co/AA0EI4gnYe https://t.co/8ZB9cUnTpS

14 Sep 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.